Literature DB >> 1388120

Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients.

S M Kelsey1, B Weinhardt, P W Collins, A C Newland.   

Abstract

Teicoplanin plus ciprofloxacin was compared with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients. A favourable response was seen in 78% of patients receiving teicoplanin plus ciprofloxacin and in 49% receiving gentamicin plus piperacillin (p less than 0.05). When microbiologically documented episodes were analysed separately, the response to teicoplanin plus ciprofloxacin was favourable in 81% of patients whereas only 35% responded favourably to gentamicin plus piperacillin (p = 0.034). Gram-positive organisms accounted for 76% of bacterial isolates, Staphylococcus epidermidis being the most common pathogen. Ten of 12 (83%) Staphylococcus epidermidis infections resolved when treated with teicoplanin plus ciprofloxacin as compared with 2 of 8 (25%) treated with gentamicin plus piperacillin. Teicoplanin is at least as effective as gentamicin plus piperacillin in the empirical treatment of febrile neutropenic patients and may be more effective in situations where gram-positive organisms are prevalent. The high incidence of gram-positive infections in our unit justifies the use of an agent with specific activity against gram-positive organisms in the first-line antibiotic regimen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388120     DOI: 10.1007/bf01960805

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

Review 1.  From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel.

Authors: 
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

2.  Assessment of the interaction between ciprofloxacin and teicoplanin in vitro and in neutropenic patients.

Authors:  C S Lewin; S M Kelsey; R Paton; A C Newland; S G Amyes
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

3.  Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia.

Authors:  M Rubin; J W Hathorn; D Marshall; J Gress; S M Steinberg; P A Pizzo
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

4.  Teicoplanin in empirical combined antibiotic therapy of bacteraemias in bone marrow transplant patients.

Authors:  F Menichetti; A Del Favero; G Bucaneve; F Aversa; F Baldelli; R Felicini; A Terenzi; S Pauluzzi
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

Review 5.  Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.

Authors:  J W Hathorn; M Rubin; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

6.  Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.

Authors: 
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

7.  A randomized trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients.

Authors:  R Sage; I Hann; H G Prentice; S Devereux; R Corringham; A V Hoffbrand; H Blacklock; L Stirling; M Guimaraes; E Trikka
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

Review 8.  Concept of empiric therapy with antibiotic combinations. Indications and limits.

Authors:  J Klastersky
Journal:  Am J Med       Date:  1986-05-30       Impact factor: 4.965

9.  Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients.

Authors:  A Del Favero; F Menichetti; R Guerciolini; G Bucaneve; F Baldelli; F Aversa; A Terenzi; S Davis; S Pauluzzi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

View more
  5 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 2.  A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours.

Authors:  J M Davies
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

3.  Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.

Authors:  H Giamarellou; H P Bassaris; G Petrikkos; W Busch; M Voulgarelis; A Antoniadou; E Grouzi; N Zoumbos
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 4.  Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients.

Authors:  P Van der Auwera; J Gérain
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 5.  The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials.

Authors:  V Krcméry
Journal:  Drugs       Date:  1995       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.